TERNS PHARMACEUTICALS INC (TERN) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TERN • US8808811074

38.19 USD
+0.21 (+0.55%)
At close: Feb 10, 2026
38.63 USD
+0.44 (+1.15%)
After Hours: 2/10/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, TERN scores 3 out of 10 in our fundamental rating. TERN was compared to 191 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for TERN as it has an excellent financial health rating, but there are worries on the profitability. TERN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TERN had negative earnings in the past year.
  • TERN had a negative operating cash flow in the past year.
  • In the past 5 years TERN always reported negative net income.
  • In the past 5 years TERN always reported negative operating cash flow.
TERN Yearly Net Income VS EBIT VS OCF VS FCFTERN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • TERN has a Return On Assets (-31.31%) which is comparable to the rest of the industry.
  • The Return On Equity of TERN (-33.24%) is better than 61.26% of its industry peers.
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROIC N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
TERN Yearly ROA, ROE, ROICTERN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TERN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TERN Yearly Profit, Operating, Gross MarginsTERN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • TERN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for TERN has been increased compared to 5 years ago.
  • There is no outstanding debt for TERN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TERN Yearly Shares OutstandingTERN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TERN Yearly Total Debt VS Total AssetsTERN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 114.39 indicates that TERN is not in any danger for bankruptcy at the moment.
  • TERN's Altman-Z score of 114.39 is amongst the best of the industry. TERN outperforms 98.95% of its industry peers.
  • TERN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 114.39
ROIC/WACCN/A
WACCN/A
TERN Yearly LT Debt VS Equity VS FCFTERN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 19.52 indicates that TERN has no problem at all paying its short term obligations.
  • TERN has a Current ratio of 19.52. This is amongst the best in the industry. TERN outperforms 89.53% of its industry peers.
  • TERN has a Quick Ratio of 19.52. This indicates that TERN is financially healthy and has no problem in meeting its short term obligations.
  • TERN has a Quick ratio of 19.52. This is amongst the best in the industry. TERN outperforms 89.53% of its industry peers.
Industry RankSector Rank
Current Ratio 19.52
Quick Ratio 19.52
TERN Yearly Current Assets VS Current LiabilitesTERN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 12.71% over the past year.
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -4.19% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y2.11%
EPS Next 2Y-3.62%
EPS Next 3Y-9.79%
EPS Next 5Y-4.19%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TERN Yearly Revenue VS EstimatesTERN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
TERN Yearly EPS VS EstimatesTERN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TERN. In the last year negative earnings were reported.
  • Also next year TERN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TERN Price Earnings VS Forward Price EarningsTERN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TERN Per share dataTERN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • TERN's earnings are expected to decrease with -9.79% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.62%
EPS Next 3Y-9.79%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TERN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TERNS PHARMACEUTICALS INC

NASDAQ:TERN (2/10/2026, 8:00:00 PM)

After market: 38.63 +0.44 (+1.15%)

38.19

+0.21 (+0.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-10
Earnings (Next)03-18
Inst Owners78.95%
Inst Owner Change-2.95%
Ins Owners0.22%
Ins Owner Change13.02%
Market Cap3.44B
Revenue(TTM)N/A
Net Income(TTM)-94.44M
Analysts84.71
Price Target54.63 (43.05%)
Short Float %18.81%
Short Ratio4.84
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.4%
Min EPS beat(2)10.7%
Max EPS beat(2)12.1%
EPS beat(4)4
Avg EPS beat(4)13.96%
Min EPS beat(4)8.96%
Max EPS beat(4)24.07%
EPS beat(8)8
Avg EPS beat(8)12.04%
EPS beat(12)10
Avg EPS beat(12)9.13%
EPS beat(16)14
Avg EPS beat(16)10.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)238.39%
EPS NQ rev (1m)0.34%
EPS NQ rev (3m)5.64%
EPS NY rev (1m)0.08%
EPS NY rev (3m)3.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 12.11
P/tB 12.11
EV/EBITDA N/A
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.21
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.87
OCFYN/A
SpS0
BVpS3.15
TBVpS3.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.31%
ROE -33.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.35%
ROA(5y)-28.14%
ROE(3y)-27.6%
ROE(5y)-31.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr -0.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.52
Quick Ratio 19.52
Altman-Z 114.39
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)29.77%
Cap/Depr(5y)60.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.57%
EPS Next Y2.11%
EPS Next 2Y-3.62%
EPS Next 3Y-9.79%
EPS Next 5Y-4.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.93%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.92%
EBIT Next 3Y-16.74%
EBIT Next 5Y-9.07%
FCF growth 1Y-31.66%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.76%
OCF growth 3YN/A
OCF growth 5YN/A

TERNS PHARMACEUTICALS INC / TERN FAQ

Can you provide the ChartMill fundamental rating for TERNS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to TERN.


What is the valuation status of TERNS PHARMACEUTICALS INC (TERN) stock?

ChartMill assigns a valuation rating of 0 / 10 to TERNS PHARMACEUTICALS INC (TERN). This can be considered as Overvalued.


How profitable is TERNS PHARMACEUTICALS INC (TERN) stock?

TERNS PHARMACEUTICALS INC (TERN) has a profitability rating of 1 / 10.


What is the financial health of TERNS PHARMACEUTICALS INC (TERN) stock?

The financial health rating of TERNS PHARMACEUTICALS INC (TERN) is 8 / 10.